Eternal Medical (01501.HK) plans to acquire the controlling stake of Hangzhou Weiqiang Medical Technology to further improve the company's product layout in the field of aortic and peripheral vascular intervention and implantation.

Zhitong Finance APP news, Yingtai Medical (01501.HK) announced that on May 21, 2025 (after trading hours), the company, Chenyue Weixin, the target company Hangzhou Weiqiang Medical Technology Co., Ltd., a Cayman Islands company, a Hong Kong company, and the founding shareholders have entered into a formal acquisition agreement. According to this agreement, the company and Chenyue Weixin (as the buyer) conditionally agree to purchase a total of 81.83% of the equity of the target company from the Hong Kong company (as the seller), with a total consideration of approximately 513 million yuan. The company will acquire a controlling stake of 51.70% of the equity of the target company, with a consideration of approximately 324 million yuan, but it is subject to the completion or waiver of conditions precedent before it can be finalized. After completion, the target company will become a non-wholly owned subsidiary of the company, and after the target company becomes a non-wholly owned subsidiary of the company, the company and Chenyue Weixin (as the buyer) will further invest no less than 150 million yuan in the target company.